Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.40 |
| ▸ | GFER | P55789 | 4/20 | 0.40 |
| ▸ | GLA | P06280 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25027267 | 1.00 | MAPT (0.43) | MAPTSMN1; SMN2TP53KDM4EGFER | |
| SCHEMBL29227209 | 0.91 | MAPT (0.48) | MAPTSMN1; SMN2TP53KDM4EGFER | |
| SCHEMBL30248444 | 0.91 | MAPT (0.45) | MAPTSMN1; SMN2TP53KDM4EGFER | |
| SCHEMBL25028076 | 0.91 | MAPT (0.45) | MAPTSMN1; SMN2TP53KDM4EGFER | |
| SCHEMBL25028040 | 0.90 | MAPT (0.47) | MAPTSMN1; SMN2TP53KDM4EGFER | |
| SCHEMBL30248582 | 0.90 | MAPT (0.47) | MAPTSMN1; SMN2TP53KDM4EGFER | |
| SCHEMBL25028042 | 0.90 | MAPT (0.48) | MAPTSMN1; SMN2TP53KDM4EGFER | |
| SCHEMBL29227188 | 0.90 | MAPT (0.48) | MAPTSMN1; SMN2TP53KDM4EGFER | |
| SCHEMBL30248409 | 0.90 | MAPT (0.48) | MAPTSMN1; SMN2TP53KDM4EGFER | |
| SCHEMBL29227011 | 0.90 | MAPT (0.48) | MAPTSMN1; SMN2TP53KDM4EGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384268-B1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT LTD (IN) | 2026-03-18 | — | — | EP | claimed |
| EP-4384268-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | Curadev Pharma Pvt. Ltd. (IN) | 2024-06-19 | — | — | EP | claimed |
| CN-118019738-A | Small molecule urea derivatives as STING antagonists | 库拉德夫制药私人有限公司 | 2024-05-10 | — | — | CN | claimed |
| WO-2023017452-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-02-16 | — | — | WO | claimed |
| US-20240360119-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2024-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360119-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | STING1, CGAS, SSB | MAPT 2509/4885SMN1; SMN2 1263/4885TP53 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.